First single breast cancer study to show significant survival,benefit for women switching from tamoxifen to Arimidex ( ias ConsultantOncologist and Professo...)

First single breast cancer study to show significant survival,benefit for women switching from tamoxifen to Arimidex

ias, Consultant Oncologist and Professor of Cancer medicine, University College London. “These data confirm that women who have not had the advantage of starting their adjuvant therapy with an aromatase inhibitor and are currently taking tamoxifen should be switched to anastrozole, to give them the best chance of living cancer-free for longer. In my view women with hormone-receptor positive early breast cancer should be offered the opportunity to receive an aromatase inhibitor like anastrozole immediately after surgery and chemotherapy to provide the best protection against their cancer returning.”

Anastrozole cuts recurrence when used as initial adjuvant therapy

These data reinforce the efficacy and tolerability benefits of anastrozole over tamoxifen seen in the ATAC (Arimidex, Tamoxifen, Alone or in Combination) study, which compared 5 years initial adjuvant therapy with anastrozole versus 5 years’ tamoxifen, and showed that prescribing anastrozole from the start significantly reduces the risk of recurrence. There is a 26% reduction in the risk of recurrence compared with tamoxifen, meaning that 1 in 4 recurrences are prevented by using anastrozole instead of tamoxifen at the start of treatment, when the risk of recurrence is highest. [ii], [iii], [iv], [v]

Furthermore, data from ATAC show that the majority of the recurrences and also of the serious adverse events associated with tamoxifen occur within the first 2.5 years of treatment, emphasising the importance of using the treatment that is more effective and better tolerated from the outset.

Anastrozole remains the only AI to have demonstrated a superior risk:benefit profile compared with tamoxifen over the full 5 year treatment period and beyond, and should establish anastrozole as the emerging gold standard of care for postmenopausal women with early breast cancer. 2

- Ends -

Notes to editors:

* ATAC – ‘Arimidex’, Tamoxifen,
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
11. Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report

Post Your Comments:

( ias ConsultantOncologist and Professo...)First single breast cancer study to show significant survival,benefit for women switching from tamoxifen to Arimidex,Health